Agenus

Agenus and Noetik announced a research collaboration to develop predictive biomarkers for the BOT/BAL immunotherapy combination using AI-powered virtual cell models.

Agenus' botensilimab and balstilimab combination achieved 100% pathological complete response rates in dMMR colorectal cancer patients at higher doses, demonstrating breakthrough activity in microsatellite stable "cold tumors."

ImmunoGenesis has dosed the first subject in a Phase I/II trial evaluating IMGS-101 (evofosfamide) in combination with checkpoint inhibitors balstilimab and zalifrelimab at MD Anderson Cancer Center.

Agenus will showcase interim data from a Phase 2 study combining BOT/BAL with iNKT cell therapy AgenT-797 in refractory gastric cancer patients at the AACR IO Annual Meeting.

Agenus's botensilimab/balstilimab combination therapy demonstrated strong efficacy in colorectal cancer treatment, achieving a 65% pathologic response rate and 38% complete response rate across all patients.

MiNK Therapeutics' agenT-797, combined with botensilimab and balstilimab, demonstrates robust immune activation in refractory gastroesophageal cancer.

Preliminary phase 2 data shows balstilimab combined with botensilimab yields a higher objective response rate in MSS mCRC patients without liver metastases.

Japan's MHLW has approved GSK's Arexvy vaccine for adults aged 50-59 at increased risk of RSV, expanding its previous authorization for those 60 and older.

Agenus executives are being sued for allegedly misleading the public about clinical trial results for a metastatic colorectal cancer treatment.

CARsgen completed enrollment in a pivotal Phase 2 trial of satricabtagene autoleucel (satri-cel), a CLDN18.2-targeted CAR-T therapy, for advanced gastric/gastroesophageal cancer.